A new antibody-drug conjugate aimed at two cancer-associated receptors has outperformed single-agent chemotherapy in a late-stage breast-cancer trial. The result is clinically substantial, but it does not yet answer whether patients live longer.
Results presented on 23 October 2026 and published in The Lancet come from PANKU-Breast01, a randomised Phase 3 study of izalontamab brengitecan, known as iza-bren or BL-B01D1. The trial involved people in China with unresectable locally advanced, recurrent or metastatic hormone-receptor-positive, HER2-negative breast cancer that had progressed after at least one previous chemotherapy line. The companies’ announcement provides the same endpoint and safety summary.
A guided payload with two addresses
Antibody-drug conjugates, or ADCs, combine a targeting antibody with a potent cell-killing payload. The antibody is intended to find cancer cells more selectively than conventional chemotherapy; after the complex is internalised, the payload is released.
Iza-bren is bispecific: it recognises EGFR and HER3, two receptors involved in growth and survival signalling in many epithelial cancers. Its topoisomerase-1-inhibitor payload then creates lethal DNA stress inside targeted cells. The drug is also designed to block signalling through the two receptors.
The Phase 3 result in numbers
The open-label PANKU-Breast01 trial, NCT06343948, assigned 190 participants to iza-bren and 193 to chemotherapy chosen by the treating physician. An independent central review assessed imaging, reducing—but not eliminating—the bias that can arise when patients and clinicians know which treatment was given.
After a median 15.2 months of follow-up for the primary endpoint, median progression-free survival was 8.2 months with iza-bren and 4.0 months with chemotherapy. The hazard ratio was 0.41, corresponding to a 59% reduction in the instantaneous risk of progression or death during the observed period. That statistic does not mean 59% of patients were cured or that every patient gained the same amount of time.
Confirmed tumour responses occurred in 40.5% of the iza-bren group and 20.2% of the chemotherapy group. Median duration of response was 6.9 months versus 4.2 months. Overall-survival data were immature at the interim analysis, so a survival advantage has not yet been established.
Safety and the regulatory gap
Grade 3 or worse treatment-related adverse events were mainly blood-related. The companies said 1.6% of participants stopped iza-bren because of treatment-related adverse events. Two patients, or 1.1%, developed adjudicated grade 1 or 2 interstitial lung disease, an inflammatory lung complication watched closely with several ADCs.
The comparator matters. This trial shows an advantage over single-agent chemotherapy in a heavily pretreated population; it does not establish superiority to every modern targeted therapy or ADC in earlier treatment settings. The study was also conducted in mainland China, so regulators and clinicians will examine whether results generalise across broader populations and treatment patterns.
Dual targeting could widen—but also complicate—the window
Recognising two receptors may help an ADC bind tumours whose cells express EGFR and HER3 unevenly. It could also give the drug more routes into cancer cells after resistance has developed. That biological rationale is attractive, but receptor expression in normal tissues can influence toxicity, and a response across a trial population does not identify which individual tumours depend most on either target.
Biomarker analyses may therefore be as important as the headline average. If researchers can determine which expression patterns predict benefit or lung and blood toxicity, a dual-target ADC could become more precise. Without that work, broad activity may come with unnecessary exposure for patients unlikely to respond.
Iza-bren remains investigational for this breast-cancer setting. The Phase 3 result supplies the kind of evidence that can support regulatory submissions, but presentation and publication are not approval. The next decisive pieces are mature overall-survival data, longer safety follow-up and the conclusions of regulators reviewing the full dataset.
Leave a Reply